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Background.BKvirus(BKV)infectionisacommoncomplicationfollowingkidneytransplantation.Immunosuppressionreduction
is the cornerstone of treatment while adjuvant drugs have been tried in small uncontrolled studies. We sought to examine our
center’s experience with the use of ciprofloxacin in patients with persistent BKV infection. Methods. Retrospective evaluation
of the effect of a 30-day ciprofloxacin course (250mg twice daily) on BKV infection in kidney transplant recipients who had
been diagnosed with BK viruria ≥106 copies/mL and viremia ≥500 copies/mL and in whom the infection did not resolve after
immunosuppressionreductionand/ortreatmentwithotheradjuvantagents.BKVinplasmaandurinewasevaluatedafter3months
following treatment with ciprofloxacin. Results. Nine kidney transplant recipients received ciprofloxacin at a median of 130 days
following the initial reduction in immunosuppression. Three patients showed complete viral clearance and another 3 had a ≥50%
decreaseinplasmaviralload.NoseriousadverseeventssecondarytociprofloxacinwerereportedandnograftswerelostduetoBKV
up to 1 year after treatment. Conclusion. Ciprofloxacin may be a useful therapy for persistent BKV infection despite conventional
treatment. Randomized trials are required to evaluate the potential benefit of this adjuvant therapy.
1. Introduction
BK polyomavirus (BKV) is a common pathogen of kidney
transplant recipients, which can result in impaired graft
function and inferior graft survival [1]. Approximately 30%,
11–13%, and 8% of kidney transplant recipients develop
BK viruria, viremia, and BK virus associated nephropathy
(BKVAN), respectively [1–3]. Graft loss rates have been
reported to be as high as 30–50% following a diagnosis
of BKVAN [1, 4], although more recent data indicate that
with early diagnosis of BK viremia or viruria using regular
screening, the majority of patients respond favorably [5].
However,BKVinfectioncontinuestohaveamajorimpacton
graft function with nearly 25% of infected patients showing a
sustained increase in serum creatinine of at least 50% com-
pared to that observed at the time of diagnosis [6]. Several
donor and recipient risk factors for the development of BKV
infection have been identified and of these, a high burden of
immunosuppression appears to be the most important [7].
A strategy of immunosuppression reduction is therefore
considered the cornerstone of treatment for BKV infection
[8], although a uniform standardized protocol has not yet
been established [2, 9]. The inability to clear this virus
despite a reduction in immunosuppression has led to a
variety of additional agents with possible anti-BK activity
being utilized as adjuvant therapy including leflunomide,
cidofovir, and intravenous immunoglobulin (IVIG) [10].
All of these agents have been reported to be beneficial in
anecdotal cases. However, the use of these agents has been
mostly limited by pharmacologic and logistical issues. IVIG
isexpensive,potentiallynephrotoxic,andneedstobeadmin-
istered intravenously over several hours. Leflunomide has
significant hematologic and hepatic toxicities and requires
therapeutic drug monitoring due to variable interpatient
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pharmacokinetics, while cidofovir is highly nephrotoxic and
appears to have minimal in vitro antiviral activity against
BKV.
Fluoroquinolones have been reported to display anti-
BKV properties through inhibition of the large T antigen
(Tag)helicaseactivity[11].In vitro,fluoroquinolonesnotonly
reduce BKV DNA replication and the associated expression
of viral proteins such as Tag but also lower the cell release
of viral progeny by more than 90% [12]. Several studies have
explored the efficacy of fluoroquinolones for the prevention
and treatment of BKV-associated hemorrhagic cystitis after
hematopoietic stem cell transplantation, which they found
to be reasonably successful [13, 14]. On the other hand,
a recently published multicenter, randomized, prospective
trial utilizing a 30-day course of levofloxacin compared to
placebo in kidney transplant recipients for the treatment of
BKviremiafoundnoimprovementinBKviralloadreduction
or renal allograft function [15]. However, in this study the
immunosuppression reduction was not standardized and all
patients had newly diagnosed BK viremia.
Given the accumulated evidence in the literature indicat-
ing in vitro activity of fluoroquinolones against BKV and the
mixed data currently available on their clinical efficacy for
the treatment of BKV infection, we decided to examine our
own experience. The aim of our study was to retrospectively
evaluate the effect of adding a 30-day course of ciprofloxacin
to the treatment of persistent BKV infection in kidney trans-
plant recipients who were refractory to immunosuppression
reduction and treatment with other adjuvant agents.
2. Methods
2.1. Study Design and Patient Population. Th i si sas i n g l e -
centerretrospectivestudyofkidneytransplantrecipientswith
refractoryBKVinfectionwhoreceivedadjuvanttherapywith
ciprofloxacin 250mg orally twice daily for 30 days. Patients
were identified through a search of an electronic database
of transplant recipients at UCSF Medical Center and had
receivedakidneytransplantbetweenJuly2009andJune2010.
Thistimeframewasselectedaswecollectedinformationdur-
ing those dates in a central database on all UCSF transplant
recipients to evaluate our center specific BKV outcomes and
treatment strategies. Refractory BKV infection was defined
as persistently detectable viremia (≥500copies/mL) and high
grade viruria (≥10
6 copies/mL) despite immunosuppression
reductionandtheuseofotheradjuvantagents.Thisstudywas
approved by our institutional review board as a retrospective
analysis and informed consent was therefore not required.
Outpatient and inpatient medical records were reviewed,
including clinic visit notes, hospital notes, discharge sum-
maries, and medication histories. Data obtained included
patient demographics, transplant characteristics, laboratory
and pathology results, and BKV urine and plasma PCR. The
primary end-point was BKV plasma clearance, defined as an
undetectable plasma viral load, 3 months after the initiation
of ciprofloxacin. Secondary end-points included the percent
reduction in BK viremia and the number of patients with
>50% reduction in BK viremia 3 months after the initiation
of ciprofloxacin as well as renal allograft function 3, 6, 9, and
12 months after the initiation of ciprofloxacin.
2.2. BKV Monitoring. The BKV screening protocol at our
institution consists of monitoring quantitative BKV DNA
P C Ri nu r i n ea n dp l a s m aa t1 ,3 ,6 ,9 ,a n d1 2m o n t h s
after transplantation using the Focus 3M Integrated Cycler.
ScreeningisconsideredpositiveatBKviruria≥10
6 copies/mL
and/or viremia ≥500 copies/mL. The diagnosis of BKVAN is
madebyakidneyallograftbiopsyshowingpositiveimmuno-
histochemical staining for the SV-40 large T antigen with
or without findings consistent with viral-mediated tubular
epithelial cell damage and interstitial inflammation. Biopsies
are performed at 6 months after transplantation for surveil-
lance and at any other time for clinical indications such as
elevated serum creatinine or persistently high BK viremia
despite therapeutic interventions.
2.3. BKV Management. Our initial approach to BKV infec-
tion consists of a reduction in immunosuppression. The first
step is a 50% decrease in the dose of the antimetabolite
drug. Monthly BKV monitoring is performed until infection
resolution, defined as undetectable BK viremia. If this goal
is not achieved within 1–3 months, physicians may choose
to further lower or discontinue the antimetabolite, lower
the calcineurin inhibitor (CNI) trough goal, or switch from
tacrolimus to cyclosporine. If a second round of immuno-
suppression reduction is not effective, adjuvant treatment
with IVIG, cidofovir, leflunomide, and/or ciprofloxacin is
considered.
3. Results
We identified 9 kidney transplant recipients with persis-
tent BKV infection despite immunosuppression reduction,
who subsequently received a 30-day course of ciprofloxacin.
Baseline demographic and transplant characteristics of these
recipients are summarized in Table 1. There were 5 men
and 4 women. Seven received their kidney transplant from
a deceased donor. Only 1 patient received a ureteral stent.
All received antibody induction: rabbit thymoglobulin in 3
patients and basiliximab in 6 patients. Initial maintenance
immunosuppression consisted of a CNI, mycophenolate
mofetil (MMF), and prednisone in 7 of the 9 patients while
the remaining 2 patients underwent early corticosteroid
withdrawal and were maintained on only a CNI and MMF.
One patient experienced an episode of antibody-mediated
rejection which occurred prior to the BKV infection.
MediantimetothefirstscreenpositivityofBKVinfection
was95daysposttransplantation(range31to224days).Serum
creatinine at the time of diagnosis ranged between 0.54 and
2.12mg/dL. All patients had high-grade viruria and viremia
at diagnosis. Management of immunosuppression and use of
other antiviral therapies are summarized in Table 2. MMF
had been reduced in all patients and then withdrawn com-
pletely in 6 of them. Leflunomide therapy replaced MMF in
twoofthoseinwhomMMFwasdiscontinued.Eightpatients
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ciprofloxacin. Ciprofloxacin 250mg twice daily for 30 days
wasaddedtotheothertreatmentsatthephysician’sdiscretion
at a median of 130 days (range 59 to 379 days) following the
diagnosis of BKV infection. All patients had persistent BK
viremia at the time of initiation of ciprofloxacin. From the
initialdiagnosisofBKviremiatothestartofciprofloxacin,BK
viremia had improved in 5 patients, worsened in 2 patients,
and was unchanged in 2 patients.
All 9 patients underwent a renal allograft biopsy for
cause after the BKV infection was diagnosed, and this
demonstrated BKVAN in 7 of them. Ciprofloxacin was given
b e f o r et h ed i a g n o s i so fB K V A Ni n4p a t i e n t s( r a n g e :9 – 6 1
days; median 48 days) and after the diagnosis of BKVAN in 3
p a t i e n t s( r a n g e :2 5 – 9 3d a y s ;m e d i a n4 5d a y s ) .Th r e ep a t i e n t s
demonstrated complete resolution of viremia and another 3
had a decrease of more than 50% in plasma viral load at
3 months following the initiation of ciprofloxacin treatment
(Table 3).Oftheremaining3patients,2hadanincreaseinthe
plasma viral load and 1 had a decrease of <50% at 3 months.
The average reduction in viral load from the initiation of
ciprofloxacin to month 3 was 58.8%. A higher percentage of
patientswhohadalowerlevelofBKviremiafromthetimeof
initial diagnosis to starting ciprofloxacin had more than 50%
reduction of BK viremia 3 months after ciprofloxacin (100%)
compared to those patients with the same or higher level of
B Kv i r e m i aa tt h es t a r to fc i p r o fl o x a c i nc o m p a r e dt ot h et i m e
of the initial diagnosis (25%; 𝑃 = 0.48).
Overall, renal function remained relatively stable or
improved in most patients after ciprofloxacin treatment with
ameanserumcreatinineof1.67±1.32mg/dLattheinitiation
of ciprofloxacin compared to 1.61±0.85mg/dL one year after
ciprofloxacin treatment (𝑃 = 0.84). However, serum creati-
nine rose significantly in patient 3 from 1.48 to 2.97mg/dL
(Figure 1). No allografts were lost due to BKV infection up to
1yearaftertheinitiationofciprofloxacin.Therewerenocases
of tendonitis or tendon rupture, Clostridium difficile colitis,
or ciprofloxacin-resistant infections during the ciprofloxacin
treatment and assessment periods.
4. Discussion
B K Vi saw e l l - r e c o g n i z e di n f e c t i o ni nk i d n e yt r a n s p l a n t
recipients, with known adverse effects on graft function and
long-term graft survival. There is general consensus that
immunosuppression reduction is the first line treatment for
newly diagnosed BKV infection [8]. On the other hand,
despite multiple published reports of different adjuvant ther-
apies for refractory cases, a clear advantage of one drug or
agent has yet to be demonstrated. In this report, we have
described our experience with a novel treatment approach
utilizing adjuvant ciprofloxacin for the management of per-
sistent BKV infection in kidney transplant recipients who
have failed to resolve the infection with alternative measures.
Ourreportshowsthatinamajority(67%)ofpatientswith
persistent BKV infection despite immunosuppression reduc-
tion, there was either a significant reduction or complete
resolution of BK viremia after the addition of ciprofloxacin.
At the same time, no adverse events of therapy such as
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30 days after ciprofloxacin.
tendonitis or Clostridium difficile colitis were noted. Addi-
tionally, no cases of fluoroquinolone-resistant urinary tract
infections occurred in the follow-up period. Overall, renal
function remained stable and no renal allografts were lost
due to BKV infection within 1 year of the ciprofloxacin treat-
ment.Ciprofloxacintreatmentwaswelltoleratedwithoutany
s e r i o u ss i d ee ff e c t si no u rs m a l lg r o u po fp a t i e n t s .C l i n i c a l l y ,
the fluoroquinolone antibiotics represent a convenient and
relatively inexpensive class of medications that could treat
persistent BKV infections with a low incidence of adverse
events.
We readily acknowledge the limitations of our study.
This is a descriptive case series with a small number of
patients and retrospective data analysis. Since ciprofloxacin
was used only in patients with persistent BKV infection, we
could not examine the effect of this treatment as a de novo
early therapy. In vitro evidence of the inhibitory effect of
fluoroquinolones on BK viral replication has been previously
demonstrated [11, 16]. Several studies have explored the
efficacyoffluoroquinolonesforthepreventionandtreatment
of BKV-associated hemorrhagic cystitis after hematopoietic
stem cell transplantation and found fluoroquinolones to be
reasonably successful [13, 14]. In the hematopoietic stem
cell transplant population, those who received 50 to 60
days of oral ciprofloxacin prophylaxis at 500mg twice daily
demonstrated a decrease in peak BK viruria early after trans-
plantation (range: 7–39 days) and significantly lower rates of
hemorrhagic cystitis [13, 14]. The data in the hematopoietic
stem cell transplant population suggests that a higher dose of
ciprofloxacinmaybemoreeffectivethanwhatwasutilizedin
ourstudy.Asinglepublishedreportutilizingfluoroquinolone
treatmentfordenovoBKVinfectioninrenaltransplantrecip-
ients demonstrated clinical efficacy [17]. However, a recently
reported randomized, double-blind clinical trial found that a6 Journal of Transplantation
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30-day course of levofloxacin did not significantly improve
BK viral load reduction or renal allograft function when
used in addition to overall reduction of immunosuppression
[15]. The patient population in this report differs from ours
in one important regard: they received levofloxacin as the
initial treatment for BKV infection, whereas our patients
received ciprofloxacin after they had failed to clear BK
viremia despite immunosuppression reduction and other
adjuvant measures. Of note, in our series, we did not find
a significant difference in treatment response between those
whoreceivedciprofloxacinearly(<90daysafterthediagnosis
of BKV infection) and those who received it later.
Finally, the lack of a control group and the diversity of
other anti-BKV therapies that patients had received previ-
ously make it difficult to isolate the specific effect of the
ciprofloxacin treatment. This point is also noted in the fact
that the most pronounced effect was seen with ciprofloxacin
in patients who already had improving levels of BK viremia,
making it difficult to separate out the effect of ciprofloxacin
versus aggressive immunosuppression reduction. Addition-
ally,whenweexaminedtheeffectofciprofloxacinbythestage
ofevolutionofBKviremiapriortotreatment,wefoundthata
completeclearanceofBKviremiaat3monthsaftertreatment
withciprofloxacinwasobservedin3outof5patientswithlow
but persistent (<10,000 copies/mL) BK viremia but in 0 out
of4patientswithhighBKviremia(>10,000copies/mL).One
possibilityisthatalongercourseofciprofloxacinisneededto
achieve a therapeutic response in this group of patients with
high grade BK viremia.
5. Conclusions
Ciprofloxacin may be a useful therapeutic tool for BKV
infection refractory to conventional treatment. Larger, ran-
domizedcontrolledtrialsareneededtodemonstratetheexact
clinical efficacy of ciprofloxacin and other fluoroquinolones
in this group of patients. The optimal timing for initiation
of treatment, the most efficacious dose and duration of
antibiotic treatment, and the patient characteristics and viral
subtypes that could potentially predict response to this form
of treatment remain to be determined.
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